UK markets open in 6 hours 33 minutes

Bone Therapeutics SA (BNZPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.20000.0000 (0.00%)
At close: 10:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.2000
Open4.2000
BidN/A x N/A
AskN/A x N/A
Day's range4.2000 - 4.2000
52-week range4.2000 - 4.2600
Volume240
Avg. volume0
Market capN/A
Beta (5Y monthly)0.25
PE ratio (TTM)N/A
EPS (TTM)-0.6680
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Bone Therapeutics appoints Lieve Creten as interim Chief Financial Officer

    REGULATED INFORMATION Gosselies, Belgium, 21 September 2021, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has appointed Lieve Creten, as interim Chief Financial Officer (CFO), succeeding Jean-Luc Vandebroek. Bone Therapeutics has appointed Lieve Creten as an interim CFO, effective 21 September 2021. Lieve Creten succeeds Jean-Luc Vandebroek, who will continue to ser

  • Globe Newswire

    Bone Therapeutics reports half year 2021 results

    REGULATED INFORMATION The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Bone Therapeutics in the section ‘Financial information’. Bone Therapeutics publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the Frenc

  • Globe Newswire

    Bone Therapeutics SA reacts to the press release issued by Hybrigenics

    Gosselies, Belgium, 7 September, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, wishes to respond to a recent press release issued by Hybrigenics (Euronext Paris - ALHYG) following very preliminary contacts made at the initiative of Hybrigenics to examine the combination of certain activities within Bone Therapeutics. Similar to other strategic opportunities that are presented to Bone T